Nuova ricerca

CIRO POLIZZI

DOCENTE A CONTRATTO presso: Dipartimento di Economia "Marco Biagi"


Home | Curriculum(pdf) | Didattica |


Pubblicazioni

2018 - Atazanavir and darunavir in pregnant women with HIV: Evaluation of laboratory and clinical outcomes from an observational national study [Articolo su rivista]
Floridia, M.; Masuelli, G.; Ravizza, M.; Tassis, B.; Cetin, I.; Sansone, M.; Antoni, A. D.; Simonazzi, G.; Maccabruni, A.; Francisci, D.; Frisina, V.; Liuzzi, G.; Dalzero, S.; Tamburrini, E.; Di Lorenzo, F.; Sterrantino, G.; Meli, M.; Campolmi, I.; Vichi, F.; Del Pin, B.; Marocco, R.; Mastroianni, C.; S. Mercurio, V.; Zanaboni, D.; Guaraldi, G.; Nardini, G.; Stentarelli, C.; Beghetto, B.; Antoni, A. M. D.; Molinari, A.; Crisalli, M. P.; Donisi, A.; Piepoli, M.; Cerri, V.; Zuccotti, G.; Giacomet, V.; Coletto, S.; Di Nello, F.; Madia, C.; Placido, G.; Milini, P.; Savalli, F.; Portelli, V.; Sabbatini, F.; Papalini, C.; Bernini, L.; Grossi, P.; Rizzi, L.; Bernardon, M.; Maso, G.; Rizzante, E.; Belcaro, C.; Meloni, A.; Dedoni, M.; Ortu, F.; Piano, P.; Citernesi, A.; BordoniVicini, I.; Luzi, K.; Spinillo, A.; Roccio, M.; Vimercati, A.; Crupano, F. M.; Calabretti, D.; Cervi, F.; Margarito, E.; Capretti, M. G.; Marsico, C.; Faldella, G.; Martinelli, P.; Agangi, A.; Capone, A.; Maruotti, G. M.; Tibaldi, C.; Trentini, L.; Todros, T.; Brambilla, T.; Savasi, V.; Personeni, C.; Giaquinto, C.; Fiscon, M.; Rubino, E.; Franceschetti, L.; Badolato, R.; Tiso, G. C.; Genovese, O.; Cafforio, C.; Pinnetti, C.; Casadei, A. M.; Cavaliere, A. F.; Cellini, M.; Marconi, A. M.; Sacchi, V.; Ierardi, M.; Polizzi, C.; Mattei, A.; Pirillo, M. F.; Amici, R.; Galluzzo, C. M.; Donnini, S.; Baroncelli, S.; Villani, P.; Cusato, M.; Cerioli, A.; De Martino, M.; Parazzini, F.; Vella, S.
abstract

Background: Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparativedata in pregnant women are limited.We assessed the safety and activity profile of these two drugs in pregnancyusing data from a national observational study.Methods: Women with atazanavir or darunavir exposure in pregnancy were evaluated for laboratory measuresand main pregnancy outcomes (e.g. preterm delivery, low birthweight, non-elective caesarean section and neonatalgestational age-adjusted birthweight Z-score).Results: Final analysis included 500 pregnancies with either atazanavir (n"409) or darunavir (n"91) exposure.No differences in pregnancy outcomes, weight gain in pregnancy, drug discontinuations, undetectable HIV-RNA,haemoglobin, ALT, total cholesterol, HDL cholesterol and LDL cholesterol were observed between the twogroups. At third trimester, exposure to darunavir was associated with higher levels of plasma triglycerides(median 235.5 versus 179 mg/dL; P"0.032) and a higher total cholesterol/HDL cholesterol ratio (median 4.03versus 3.27; P"0.028) and exposure to atazanavir was associated with higher levels of plasma bilirubin (1.54versus 0.32 mg/dL; P<0.001).Conclusions: In this observational study, the two main HIV PIs currently recommended by perinatal guidelinesshowed similar safety and activity in pregnancy, with no evidence of differences between the two drugs in termsof main pregnancy outcomes. Based on the minor differences observed in laboratory measures, prescribingphysicians might prefer either drug in some particular situations where the different impacts of treatment onlipid profile and bilirubin may have clinical relevance.


2017 - Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series [Articolo su rivista]
Floridia, M.; Masuelli, G.; Meloni, A.; Cetin, I.; Tamburrini, E.; Cavaliere, A. F.; Dalzero, S.; Sansone, M.; Alberico, S.; Guerra, B.; Spinillo, A.; Chiado Fiorio Tin, M.; Ravizza, M.; Mori, F.; Ortolani, P.; dalle Nogare, E. R.; Di Lorenzo, F.; Sterrantino, G.; Meli, M.; Polemi, S.; Nocentini, J.; Baldini, M.; Montorzi, G.; Mazzetti, M.; Rogasi, P.; Borchi, B.; Vichi, F.; Del Pin, B.; Pinter, E.; Anzalone, E.; Marocco, R.; Mastroianni, C.; Mercurio, V. S.; Carocci, A.; Grilli, E.; Maccabruni, A.; Zaramella, M.; Mariani, B.; Natalini Raponi, G.; Guaraldi, G.; Nardini, G.; Stentarelli, C.; Beghetto, B.; Degli Antoni, A. M.; Molinari, A.; Crisalli, M. P.; Donisi, A.; Piepoli, M.; Cerri, V.; Zuccotti, G.; Giacomet, V.; Coletto, S.; Di Nello, F.; Madia, C.; Placido, G.; Vivarelli, A.; Castelli, P.; Savalli, F.; Portelli, V.; Sabbatini, F.; Francisci, D.; Bernini, L.; Grossi, P.; Rizzi, L.; Maso, G.; Airoud, M.; Soppelsa, G.; Dedoni, M.; Cuboni, C.; Ortu, F.; Piano, P.; Citernesi, A.; Bordoni Vicini, I.; Luzi, K.; Roccio, M.; Vimercati, A.; Miccolis, A.; De Gennaro, A.; Cervi, F.; Simonazzi, G.; Margarito, E.; Capretti, M. G.; Marsico, C.; Faldella, G.; Martinelli, P.; Agangi, A.; Capone, A.; Maruotti, G. M.; Tibaldi, C.; Trentini, L.; Todros, T.; Frisina, V.; Brambilla, T.; Savasi, V.; Personeni, C.; Giaquinto, C.; Fiscon, M.; Rubino, E.; Bucceri, A.; Matrone, R.; Scaravelli, G.; Genovese, O.; Cafforio, C.; Pinnetti, C.; Liuzzi, G.; Tozzi, V.; Massetti, P.; Casadei, A. M.; Cellini, M.; Castelli Gattinara, G.; Marconi, A. M.; Sacchi, V.; Ierardi, M.; Polizzi, C.; Mattei, A.; Pirillo, M. F.; Amici, R.; Galluzzo, C. M.; Donnini, S.; Baroncelli, S.; Villani, P.; Cusato, M.; Cerioli, A.; De Martino, M.; Mastroiacovo, P.; Parazzini, F.; Vella, S.
abstract

Objectives: To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures. Design: Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used. Setting: University and hospital clinics. Population: Pregnant women with HIV. Methods: Temporal trends were analysed by analysis of variance and by the Chi-square test for trend. Quantitative variables were compared by Student's t-test and categorical data by the Chi-square test, with odds ratios and 95% confidence intervals calculated. Main outcome measures: Rate of invasive testing, intrauterine death, HIV transmission. Results: Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005. Conclusions: The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment. Tweetable abstract: No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti-HIV regimens.


2017 - Rate, correlates and outcomes of repeat pregnancy in HIV-infected women [Articolo su rivista]
Floridia, M.; Tamburrini, E.; Masuelli, G.; Martinelli, P.; Spinillo, A.; Liuzzi, G.; Vimercati, A.; Alberico, S.; Maccabruni, A.; Pinnetti, C.; Frisina, V.; Dalzero, S.; Ravizza, M.; Mori, F.; Ortolani, P.; dalle Nogare, E. R.; Di Lorenzo, F.; Sterrantino, G.; Meli, M.; Polemi, S.; Nocentini, J.; Baldini, M.; Montorzi, G.; Mazzetti, M.; Rogasi, P.; Borchi, B.; Vichi, F.; Del Pin, B.; Pinter, E.; Anzalone, E.; Marocco, R.; Mastroianni, C.; Mercurio, V. S.; Carocci, A.; Grilli, E.; Zaramella, M.; Mariani, B.; Natalini Raponi, G.; Guaraldi, G.; Nardini, G.; Stentarelli, C.; Beghetto, B.; Degli Antoni, A. M.; Molinari, A.; Crisalli, M. P.; Donisi, A.; Piepoli, M.; Cerri, V.; Zuccotti, G.; Giacomet, V.; Coletto, S.; Di Nello, F.; Madia, C.; Placido, G.; Vivarelli, A.; Castelli, P.; Savalli, F.; Portelli, V.; Sabbatini, F.; Francisci, D.; Bernini, L.; Grossi, P.; Rizzi, L.; Maso, G.; Airoud, M.; Soppelsa, G.; Meloni, A.; Dedoni, M.; Cuboni, C.; Ortu, F.; Piano, P.; Citernesi, A.; Bordoni Vicini, I.; Luzi, K.; Roccio, M.; Miccolis, A.; De Gennaro, A.; Guerra, B.; Cervi, F.; Simonazzi, G.; Margarito, E.; Capretti, M. G.; Marsico, C.; Faldella, G.; Sansone, M.; Agangi, A.; Capone, A.; Maruotti, M.; Tibaldi, C.; Trentini, L.; Todros, T.; Cetin, I.; Brambilla, T.; Savasi, V.; Personeni, C.; Giaquinto, C.; Fiscon, M.; Rubino, E.; Bucceri, A.; Matrone, R.; Scaravelli, G.; Genovese, O.; Cafforio, C.; Tozzi, V.; Massetti, P.; Casadei, A. M.; Cavaliere, A. F.; Cellini, M.; Castelli Gattinara, G.; Marconi, A. M.; Sacchi, V.; Ierardi, M.; Polizzi, C.; Mattei, A.; Pirillo, M. F.; Amici, R.; Galluzzo, C. M.; Donnini, S.; Baroncelli, S.; Villani, P.; Cusato, M.; Cerioli, A.; De Martino, M.; Mastroiacovo, P.; Parazzini, F.; Vella, S.
abstract

Objectives: The aim of the study was to assess the rate, determinants, and outcomes of repeat pregnancies in women with HIV infection. Methods: Data from a national study of pregnant women with HIV infection were used. Main outcomes were preterm delivery, low birth weight, CD4 cell count and HIV plasma viral load. Results: The rate of repeat pregnancy among 3007 women was 16.2%. Women with a repeat pregnancy were on average younger than those with a single pregnancy (median age 30 vs. 33 years, respectively), more recently diagnosed with HIV infection (median time since diagnosis 25 vs. 51 months, respectively), and more frequently of foreign origin [odds ratio (OR) 1.36; 95% confidence interval (CI) 1.10–1.68], diagnosed with HIV infection in the current pregnancy (OR: 1.69; 95% CI: 1.35–2.11), and at their first pregnancy (OR: 1.33; 95% CI: 1.06–1.66). In women with sequential pregnancies, compared with the first pregnancy, several outcomes showed a significant improvement in the second pregnancy, with a higher rate of antiretroviral treatment at conception (39.0 vs. 65.4%, respectively), better median maternal weight at the start of pregnancy (60 vs. 61 kg, respectively), a higher rate of end-of-pregnancy undetectable HIV RNA (60.7 vs. 71.6%, respectively), a higher median birth weight (2815 vs. 2885 g, respectively), lower rates of preterm delivery (23.0 vs. 17.7%, respectively) and of low birth weight (23.4 vs. 15.4%, respectively), and a higher median CD4 cell count (+47 cells/μL), with almost no clinical progression to Centers for Disease Control and Prevention stage C (CDC-C) HIV disease (0.3%). The second pregnancy was significantly more likely to end in voluntary termination than the first pregnancy (11.4 vs. 6.1%, respectively). Conclusions: Younger and foreign women were more likely to have a repeat pregnancy; in women with sequential pregnancies, the second pregnancy was characterized by a significant improvement in several outcomes, suggesting that women with HIV infection who desire multiple children may proceed safely and confidently with subsequent pregnancies.


2015 - Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy [Articolo su rivista]
Floridia, M.; Mastroiacovo, P.; Ravizza, M.; Todros, T.; Chiado Fiorio Tin, M.; Marconi, A. M.; Cetin, I.; Maruotti, G. M.; Liuzzi, G.; Pinnetti, C.; Degli Antoni, A.; Spinillo, A.; Guerra, B.; Tamburrini, E.; Floridia, M.; Ravizza, M.; Tamburrini, E.; Ravizza, M.; Tamburrini, E.; Mori, F.; Ortolani, P.; dalle Nogare, E. R.; Di Lorenzo, F.; Sterrantino, G.; Meli, M.; Polemi, S.; Nocentini, J.; Baldini, M.; Montorzi, G.; Mazzetti, M.; Rogasi, P.; Borchi, B.; Vichi, F.; Del Pin, B.; Pinter, E.; Anzalone, E.; Marocco, R.; Mastroianni, C.; Mercurio, V. S.; Carocci, A.; Grilli, E.; Maccabruni, A.; Zaramella, M.; Mariani, B.; Natalini Raponi, G.; Guaraldi, G.; Nardini, G.; Stentarelli, C.; Beghetto, B.; Degli Antoni, A. M.; Molinari, A.; Crisalli, M. P.; Donisi, A.; Piepoli, M.; Cerri, V.; Zuccotti, G.; Giacomet, V.; Coletto, S.; Di Nello, F.; Madia, C.; Placido, G.; Vivarelli, A.; Castelli, P.; Savalli, F.; Portelli, V.; Sabbatini, F.; Francisci, D.; Bernini, L.; Grossi, P.; Rizzi, L.; Alberico, S.; Maso, G.; Airoud, M.; Soppelsa, G.; Meloni, A.; Dedoni, M.; Cuboni, C.; Ortu, F.; Piano, P.; Citernesi, A.; Bordoni Vicini, I.; Luzi, K.; Spinillo, A.; Roccio, M.; Vimercati, A.; Miccolis, A.; De Gennaro, A.; Guerra, B.; Cervi, F.; Puccetti, C.; Margarito, E.; Contoli, M.; Capretti, M. G.; Marsico, C.; Faldella, G.; Sansone, M.; Martinelli, P.; Agangi, A.; Capone, A.; Maruotti, G. M.; Tibaldi, C.; Trentini, L.; Todros, T.; Masuelli, G.; Frisina, V.; Cetin, I.; Brambilla, T.; Savasi, V.; Personeni, C.; Giaquinto, C.; Fiscon, M.; Rinaldi, R.; Rubino, E.; Bucceri, A.; Matrone, R.; Scaravelli, G.; Fundaro, C.; Genovese, O.; Cafforio, C.; Pinnetti, C.; Liuzzi, G.; Tozzi, V.; Massetti, P.; Casadei, A. M.; Cavaliere, A. F.; Finelli, V.; Cellini, M.; Castelli Gattinara, G.; Dalzero, S.; Sacchi, V.; Ierardi, M.; Polizzi, C.; Mattei, A.; Pirillo, M. F.; Amici, R.; Galluzzo, C. M.; Donnini, S.; Baroncelli, S.; Floridia, M.; Villani, P.; Cusato, M.; Cerioli, A.; De Martino, M.; Mastroiacovo, P.; Parazzini, F.; Tamburrini, E.; Vella, S.; Martinelli, P.; Ravizza, M.
abstract

What's already known about this topic? Exposure to antiretroviral treatment in pregnancy does not seem to increase the risk of birth defects, but there is no information on the rate of prenatal detection of such defects. What does this study adds? We provide for the first time, in a national case series, information about prenatal detection rate in women with HIV (51.6% for any major defect, 66.7% for chromosomal abnormalities, and 85% for severe structural defects).